Skip to main content


Table 3 Antibody-based therapy

From: Novel and emerging therapies for B cell lymphoma

DrugAntigen targetClassPatient populationNORRCRGrade 3 AERef
BlinatumomabCD-19, CD-3Bispecific AbDLBCL, FL, MCL3569 %
80% (FL)
71% (MCL)
55% (DLBCL)
40% (FL)
43% (MCL)
36% (DLBCL)
Leukopenia, neurologic event[33]
BlinatumomabCD-19, CD-3Bispecific AbDLBCL2536%16%Leukopenia, thrombocytopenia, neurologic event[34]
CD20-Tcb (RG6026)CD-20, CD-3Bispecific AbDLBCL,PMBCL, tFL, RT, FL6438%24%None[35]
MosunetuzumabCD-20, CD-3Bispecific AbDLBCL, tFL, FL9841%27%Anemia, neutropenia, hypophosphatemia[36]
Adct-402 (loncastuximab tesirine)CD-19ADCMCL, FL3080% (FL)
46.7% (MCL)
53.3% (FL)
26.7% (MCL)
Increased GGT, neutropenia, anemia[37]
Adct-301 (camidanlumab tesirine)CD-25ADCB cell NHL
T cell NHL
Immune-related AE: dermatitis exfoliative, thyroiditis[38]
Adct-301 (camidanlumab tesirine)CD-25ADCHL6038%24%Increased GGT, ALT, AST, and ALP, maculopapular rash, anemia, and thrombocytopenia; immune-related AE: Guillain–Barré syndrome, thyroiditis[39]
MT 3724CD-20, Shiga-like toxin-I A1Recombinant fusion protein AbDLBCL2412.5%4%None[40]
Hu5F9-G4CD-47AbDLBCL, FL2250%36%Pulmonary embolism, ITP, anemia, thrombocytopenia, neutropenia, pyrexia, chills[41]
DCDS0780ACD-79bADCDLBCL, FL, MCL, MZL4840%14%Neutropenia, thrombocytopenia, hypercalcemia[42]
177 Lu-lilotomab satetraxetanCD-37Antibody-radionuclide conjugateFL, MCL, MZL, SLL7461%26%Neutropenia, thrombocytopenia, infections[43]
  1. Abbreviations: N number of patients, ORR overall response rate, CR complete response rate, AE adverse events, DLBCL diffuse large B cell lymphoma, CLL chronic leukemic leukemia, tFL transformed follicular lymphoma, FL follicular lymphoma, WM Waldenström’s macroglobulinemia, MZL marginal zone lymphoma, RT Richter’s transformation, MCL mantle cell lymphoma, PMBL primary mediastinal B cell lymphoma, ADC antibody-drug conjugate, GGT gamma-glutamyl transferase, ITP immune thrombocytopenic purpura, AE adverse event, ALT alanine aminotransferase, ALP alkaline phosphatase, Ab antibody